This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Pharmaxis Past Earnings Performance
Past criteria checks 3/6
Pharmaxis has been growing earnings at an average annual rate of 11.5%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 15.2% per year. Pharmaxis's return on equity is 12.9%, and it has net margins of 12.3%.
Key information
11.51%
Earnings growth rate
7.44%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
-15.24%
Return on equity
12.87%
Net Margin
12.30%
Next Earnings Update
28 Jul 2023
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharmaxis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:PMXS.F Revenue, expenses and earnings (AUD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 22
16
2
15
0
30 Sep 22
18
2
15
0
30 Jun 22
16
-2
15
0
31 Mar 22
14
-16
15
0
31 Dec 21
19
-12
15
0
30 Sep 21
28
-1
16
0
30 Jun 21
24
-3
16
0
31 Mar 21
27
5
16
6
31 Dec 20
22
-4
16
-2
30 Sep 20
12
-13
16
6
30 Jun 20
13
-14
16
0
31 Mar 20
13
-21
17
7
31 Dec 19
13
-18
17
7
30 Sep 19
13
-18
16
7
30 Jun 19
12
-20
17
9
31 Mar 19
7
-27
17
9
31 Dec 18
22
-12
17
9
30 Sep 18
21
-22
17
10
30 Jun 18
49
6
16
10
31 Mar 18
51
10
16
13
31 Dec 17
37
-1
16
13
30 Sep 17
36
7
15
13
30 Jun 17
9
-18
15
15
31 Mar 17
8
-16
15
13
31 Dec 16
7
-16
15
14
30 Sep 16
8
-14
15
16
30 Jun 16
10
-16
15
15
31 Mar 16
47
16
16
17
31 Dec 15
48
14
17
15
30 Sep 15
49
21
19
15
30 Jun 15
47
18
21
13
31 Mar 15
5
-34
13
22
31 Dec 14
8
-38
25
12
30 Sep 14
5
-51
16
17
30 Jun 14
9
-52
28
7
31 Mar 14
5
-44
18
16
31 Dec 13
6
-43
25
13
30 Sep 13
4
-43
20
20
30 Jun 13
3
-44
20
24
31 Mar 13
3
-41
19
29
31 Dec 12
2
-40
19
24
30 Sep 12
2
-39
18
30
30 Jun 12
1
-39
16
24
Quality Earnings: PMXS.F has high quality earnings.
Growing Profit Margin: PMXS.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PMXS.F has become profitable over the past 5 years, growing earnings by 11.5% per year.
Accelerating Growth: PMXS.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PMXS.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: PMXS.F's Return on Equity (12.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/06/06 22:41
End of Day Share Price
2023/03/09 00:00
Earnings
2022/12/31
Annual Earnings
2022/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syntara Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.